Clinical trials: Menopausal Vasomotor Symptoms
Menopause
Hot Flash and Night Sweat Virtual Study
The purpose of this research study is to evaluate the effectiveness of the study product on vasomotor symptoms (VMS) and overall menopause symptoms in healthy women, who are perimenopausal or postmenopausal, and aged 40 - 65.
- Trial name
- NCT06289907
- Testing
- Bonafide-HF3.0
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- Bonafide Health
Hot Flashes
A Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause
This study was for women in menopause with hot flashes. Menopause, a normal part of aging, was the time of a woman's last period. Hot flashes can interrupt a woman's daily life.
- Trial name
- Skylight 4 (NCT04003389)
- Testing
- fezolinetant
- Where
- 182 sites in United States, Canada and 6 more
- Volunteers
- 1,831 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Menopausal Symptoms
Randomized Placebo Controlled Clinical Study of an Oral Product in Subjects With Menopausal Symptoms
The objective of this study is to assess the safety and effectiveness of a dietary supplement for symptom relief in subjects with menopausal symptoms over the course of five weeks of continuous daily use.
- Trial name
- NCT06787443
- Testing
- Dietary Supplement with Proprietary Herbal Extract Blend and GABA
- Where
- United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- Olly, PBC
Vasomotor Symptoms Associated With Menopause, Hot Flashes
A Study to Learn More About How Well Elinzanetant Works and How Safe it is for the Treatment of Vasomotor Symptoms (Hot Flashes) That Are Caused by Hormonal Changes Over 26 Weeks in Women Who Have Been Through the Menopause
Researchers are looking for a better way to treat women who have hot flashes after women have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the…
- Trial name
- OASIS-1 (NCT05042362)
- Testing
- Elinzanetant (BAY3427080)
- Where
- 99 sites in United States, Austria and 6 more
- Volunteers
- 396 people
- Sponsor
- Bayer
Menopausal Symptoms, Physical Activity and Sedentary Behavior
Prevalence of Menopause-associated Symptoms Throughout the Menopausal Transition in Women Aged 40 to 70 Residing in Spain and Its Relationship With Physical Activity - MdH Study
The goal of this observational study is to learn about menopause-related symptoms in women aged 40 to 70 years who live in Spain.
- Trial name
- NCT07596069
- Testing
- Reproductive stage, Physical Activity Level
- Where
- 2 sites in Spain
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Cuerpos Serranos S.L.
Hot Flashes, Hot Flash
Herbal Dietary Supplementation on Vasomotor Symptoms in Menopausal Women
The goal of this study is to evaluate the efficacy of a neurokinin 1,3 antagonist on improving vasomotor symptoms (VMS) and overall menopause symptoms in women between the ages of 40-70.
- Conditions
- Hot Flashes, Hot Flash, Hot Flushes, Menopause, Postmenopause, Hot Flushes and/or Sweats
- Trial name
- NCT07408115
- Testing
- JDS-HF3.0
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- Bonafide Health
Major Depressive Disorder, Vasomotor Symptoms
Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
This is a non-interventional study to review safety data on administration of desvenlafaxine succinate among Filipino patients with MDD and VMS per usual clinical practice within the first three years post commercial distribution.
- Trial name
- NCT01353963
- Testing
- desvenlafaxine succinate
- Where
- 3 sites in Philippines
- Volunteers
- 13 people
- Sponsor
- Pfizer
Post-menopausal Vasomotor Symptoms
Evaluation of the Pharmacokinetics and Safety of BAY3427080 (NT-814) in Post-Menopausal Women With Vasomotor Symptoms
This is a multi-center, double-blind, randomized, placebo-controlled multiple ascending dose study in post-menopausal women with vasomotor symptoms. Single ascending doses of NT-814 will be investigated in 4 cohorts.
- Trial name
- RELENT-1 (NCT02865538)
- Testing
- BAY3427080
- Where
- 3 sites in United States
- Volunteers
- 76 people
- Sponsor
- Bayer
Menopause
A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
This study will be a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial of postmenopausal subjects with an intact uterus.
- Trial name
- REPLENISH (NCT01942668)
- Testing
- Estradiol, Progesterone
- Where
- 119 sites in United States
- Volunteers
- 1,845 people
- Sponsor
- TherapeuticsMD
Vasomotor Symptoms, Menopausal Symptoms
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)
A two-part study designed to evaluate the effect of Estetrol (E4) 15 mg, 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) in the Efficacy Study Part and the safety of E4 20 mg in the Safety Study Part.
- Trial name
- E4Comfort II (NCT04090957)
- Testing
- Estetrol oral tablet
- Where
- 117 sites in United States, Canada
- Volunteers
- 1,015 people, healthy volunteers welcome
- Sponsor
- Estetra
Menopause Hot Flashes
MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women
The purpose of this study is to assess the efficacy and safety of MT-8554 for treatment of vasomotor symptoms (VMS) associated with menopause.
- Trial name
- NCT03291067
- Testing
- MT-8554 1mg, MT-8554 5mg, MT-8554 10mg
- Where
- 63 sites in United States
- Volunteers
- 375 people
- Sponsor
- Tanabe Pharma America, Inc.
Vasomotor Symptoms Associated With Menopause
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective in the treatment of moderate to severe vasomotor symptoms associated with menopause.
- Trial name
- NCT00234819
- Testing
- Bazedoxifene/Conjugated Estrogen
- Where
- 7 sites in United States
- Volunteers
- 325 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Hot Flashes
24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms
To assess the safety and efficacy of Brisdelle (paroxetine mesylate) Capsules 7.5 mg for treatment of vasomotor symptoms (VMS) associated with menopause
- Trial name
- NCT01101841
- Testing
- Brisdelle (paroxetine mesylate)
- Where
- 32 sites in United States
- Volunteers
- 570 people
- Sponsor
- Noven Therapeutics
Menopause, Vasomotor; Syndrome
Efficacy of Nano-Pso Therapy in Menopause
Vasomotor syndrome is prevalent in 85% of postmenopausal women, hormone therapy in menopause is first-line therapy, but 38% of patients have some contraindication for its use.
- Trial name
- NCT06432816
- Testing
- NANO-PSO
- Where
- Mexico
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Distribuidora Biolife SA de CV
Severe Vasomotor Symptom Associated With Menopause
Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive
To evaluate safety and efficacy of CE/BZA in real practice in Korea
- Trial name
- NCT02792504
- Where
- 20 sites in South Korea
- Volunteers
- 669 people
- Sponsor
- Pfizer
Perimenopause, Perimenopausal Depression
A Trial to Investigate the Accuracy of a Wearable Device in Collecting Data Related to Perimenopausal Symptoms in Women
The goal of this observational study is to investigate the accuracy of the device in characterizing perimenopausal and menopausal symptoms including vasomotor symptoms, anxiety, sleep quality compared to self-reported symptoms…
- Conditions
- Perimenopause, Perimenopausal Depression, Perimenopausal Insomnia, Perimenopausal Women
- Trial name
- NCT07022925
- Where
- Canada
- Volunteers
- 110 people
- Sponsor
- IdentifyHer Limited
Vasomotor Symptoms
The Effect Of Dose Titration And Dose Tapering On The Tolerability Of DVS SR In Women With Vasomotor Symptoms
Desvenlafaxine succinate (DVS SR) is a serotonin and norepinephrine reuptake inhibitor (SNRI). It is a nonhormonal option for the treatment of Vasomotor Symptoms (VMS) associated with menopause.
- Trial name
- NCT00401245
- Testing
- desvenlafaxine succinate sustained release
- Where
- 74 sites in United States, Canada
- Volunteers
- 500 people
- Sponsor
- Pfizer
Vasomotor Symptoms
Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).
This Phase 2a randomized, double-blind, placebo-controlled study evaluates the safety and efficacy of asimadoline (TP0052), a peripherally restricted selective kappa-opioid receptor agonist, for moderate to severe menopausal…
- Trial name
- NCT07042516
- Testing
- Asimadoline
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Tioga Pharmaceuticals
Vasomotor Symptoms Associated With Menopause, Healthy Volunteers
Study Evaluating ABCL635 for Vasomotor Symptoms of Menopause
The purpose of this study is to evaluate the effects of single and multiple doses of ABCL635 administered by subcutaneous (SC) injection to healthy men and to postmenopausal women with or without any vasomotor symptoms (VMS) or…
- Trial name
- NCT07118891
- Testing
- ABCL635
- Where
- 13 sites in Canada
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- AbCellera Biologics Inc.
Joint Discomfort, Joint Pain, Stiffness, Function
JDS-HF3.0 Supplementation on Menopause Related Quality of Life Outcomes in Postmenopausal Women
The goal of this interventional study is to evaluate whether the study product can help improve quality of life and reduce common menopause symptoms-such as joint discomfort, hot flashes and night sweats-in women aged 50-70.
- Conditions
- Joint Discomfort, Joint Pain, Stiffness, Function, Joint Pain, Hot Flashes
- Trial name
- NCT07238478
- Testing
- JDS-HF3.0
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Bonafide Health